rVWF +/− ADVATE for Von Willebrand Disease

Recruiting at 27 trial locations

Overseen By Takeda Contact

Age: < 18

Sex: Any

Trial Phase: Phase 3

Sponsor: Baxalta now part of Shire

Must be taking: VWF products

Must not be taking: Immunomodulatory drugs

Disqualifiers: Pseudo-VWD, VWF inhibitor, others

No Placebo Group All trial participants will receive the active study treatment (no placebo)

Pivotal Trial (Near Approval) This treatment is in the last trial phase before FDA approval

Prior Safety Data This treatment has passed at least one previous human trial

Compensation: Varies

Number of Visits: Unknown

Duration: 12-18 months

31 Participants Needed

What You Need to Know Before You Apply

What is the purpose of this trial?

The main aim of the study is to check effectiveness, side effects, and tolerability of vonicog alfa (recombinant von Willebrand factor \[rVWF\]), with or without ADVATE, in the treatment and control of nonsurgical bleeding events in pediatric participants (less than (\<)18 years of age) with severe hereditary von Willebrand disease (VWD). The participants will be treated with vonicog alfa for 12-18 months. Their von Willebrand Disease will be treated by their doctor according to their doctor's usual clinical practice. During the study, participants will be followed up at clinics or over telephone calls.

Will I have to stop taking my current medications?

The trial information does not specify if you need to stop taking your current medications. However, if you are on immunomodulatory drugs (medications that affect the immune system) other than anti-retroviral chemotherapy, you may need to stop them 30 days before joining the study.

Is the treatment with recombinant von Willebrand factor (rVWF) safe for humans?

Research shows that recombinant von Willebrand factor (rVWF) is generally safe for humans, with most patients tolerating it well. Some patients experienced mild side effects, and a few had serious issues like deep vein thrombosis (a blood clot), but no severe allergic reactions were reported. ^{1 2 3 4 5}

What makes the drug rVWF +/− ADVATE unique for treating Von Willebrand Disease?

rVWF +/− ADVATE is unique because it combines recombinant von Willebrand factor (rVWF) with or without ADVATE, a recombinant antihemophilic factor, to specifically target and treat Von Willebrand Disease by replacing the missing or defective proteins needed for blood clotting, which is different from standard treatments that may not use recombinant technology. ^{6 7 8 9 10}

What data supports the effectiveness of the drug rVWF for treating Von Willebrand Disease?

Research shows that recombinant von Willebrand factor (rVWF) is effective in treating bleeding episodes in patients with Von Willebrand Disease, with most patients experiencing successful bleed resolution and high treatment satisfaction. Additionally, rVWF has been shown to have a prolonged half-life and high structural integrity, making it a promising option for managing this condition. ^{1 4 11 12 13}

Who Is on the Research Team?

Study Director

Principal Investigator

Takeda

Are You a Good Fit for This Trial?

Children under 18 with severe hereditary von Willebrand disease (VWD) can join this trial. They must have had at least one bleed requiring treatment in the past year and agree to follow study rules. Girls who can have babies must test negative for pregnancy and use birth control.

Inclusion Criteria

I have been diagnosed with severe von Willebrand disease.

I've had a bleeding episode in the last year despite treatment with DDAVP.

I have never received VWF coagulation factor replacement therapy.

Exclusion Criteria

I have had a blood clot in the past.

I haven't taken any immune system modifying drugs in the last 30 days.

Pregnant or lactating female participants at the time of informed consent

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive vonicog alfa for non-surgical bleeding episodes over a 12 to 18-month period

12-18 months

Regular follow-ups at clinics or via telephone

Surgery

Participants undergo elective or emergency surgery with specific infusion protocols

Varies by surgery type

Pre-operative and post-operative visits

Follow-up

Participants are monitored for safety and effectiveness after treatment

Throughout the study duration of approximately 8.5 years

What Are the Treatments Tested in This Trial?

Interventions

• Antihemophilic Factor (Recombinant)
• von Willebrand factor (Recombinant)

Trial Overview The trial is testing recombinant von Willebrand Factor (rVWF), alone or with ADVATE, to treat bleeding in kids with VWD. Over 12-18 months, doctors will give treatments based on their usual practice while checking effectiveness and side effects.

How Is the Trial Designed?

Group I: On-demand Treatment Experimental Treatment 2 Interventions

Participants will receive vonicog alfa (recombinant von Willebrand factor \[rVWF\]) treatment for non-surgical bleeding episodes over a 12 to 18-month period.

Group II: Emergency Surgery Experimental Treatment 2 Interventions

Within 3 hours prior to surgery. Minor surgery: infuse every 12-24 hours for at least 48 hours based on post-operative dosing. Oral Surgery: infuse at least once within first 8-12 hours post-surgery based on post-operative dosing. Major Surgery: infuse every 12-24 hours for at least first 96 hours post-surgery based on post-operative dosing.

Group III: Elective Surgery Experimental Treatment 2 Interventions

12-24 hours prior to surgery and within 3 hours of surgery. Minor surgery: infuse every 12-24 hours for at least 48 hours based on post-operative dosing. Oral Surgery: infuse at least once within first 8-12 hours post-surgery based on post-operative dosing. Major Surgery: infuse every 12-24 hours for at least first 96 hours post-surgery based on post-operative dosing.

Who Is Running the Clinical Trial?

Baxalta now part of Shire

Lead Sponsor

Trials

111

Recruited

9,100+

Flemming Ornskov

Baxalta now part of Shire

Chief Executive Officer since 2013

MD, MPH

Ludwig N. Hantson

Baxalta now part of Shire

Chief Medical Officer since 2015

PhD

Takeda Development Center Americas, Inc.

Industry Sponsor

Trials

58

Recruited

10,800+

Published Research Related to This Trial

Recombinant von Willebrand factor (rVWF) has a significantly longer mean residence time and half-life compared to plasma-derived VWF/factor VIII (pdVWF/FVIII) in patients with von Willebrand disease, indicating a prolonged therapeutic effect.

Simulations suggest that administering rVWF can maintain FVIII activity levels above 40 IU/dL for the entire 72-hour dosing interval, making it a potentially more effective treatment option for managing bleeding episodes.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Pharmacokinetic-Pharmacodynamic Comparison of Recombinant and Plasma-Derived von Willebrand Factor in Patients with von Willebrand Disease Type 3. Bauer, A., Friberg-Hietala, S., Smania, G., et al.[2023]

In a study involving 91 adults with von Willebrand disease, recombinant von Willebrand factor (rVWF) effectively treated spontaneous and traumatic bleeds, achieving resolution in 14 out of 15 cases.

rVWF was also effective in preventing and treating surgery-related bleeds, with a resolution rate of 25 out of 58 surgeries, and no treatment-emergent adverse events were reported, indicating a strong safety profile.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Outcomes in Patients With von Willebrand Disease Receiving Recombinant von Willebrand Factor on Demand and in Surgical Settings: Chart Review. Sun, SX., Lowndes, S., Willock, R., et al.[2023]

In a post hoc analysis of a phase 3 trial involving 18 adults with type 3 von Willebrand disease, recombinant von Willebrand factor (rVWF) prophylaxis significantly reduced annualized bleeding rates by 91.6% in patients previously treated on-demand, indicating its high efficacy.

The safety profile of rVWF was favorable, with only one non-serious adverse event reported and no serious treatment-related adverse events or development of von Willebrand factor inhibitors, suggesting it is a safe option for patients.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Prophylaxis with recombinant von Willebrand factor in patients with type 3 von Willebrand disease: Results of a post hoc analysis from a phase 3 trial. Leebeek, FWG., Peyvandi, F., Tiede, A., et al.[2023]

In a phase 3 study involving patients with severe von Willebrand disease (VWD) undergoing surgery, recombinant von Willebrand factor (rVWF) demonstrated excellent or good hemostatic efficacy in 100% of cases, with 73.3% rated as excellent overall.

rVWF was well-tolerated, with most patients (89.4%) receiving it alone, achieving effective levels of endogenous factor VIII for up to 96 hours, and no severe allergic reactions were reported, indicating a favorable safety profile.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Phase 3 study of recombinant von Willebrand factor in patients with severe von Willebrand disease who are undergoing elective surgery. Peyvandi, F., Mamaev, A., Wang, JD., et al.[2023]

In a real-world study involving 111 patients with von Willebrand disease (VWD) across 31 centers in 11 countries, wilate was found to be safe and well tolerated, with 96.2% of infusions rated as 'excellent' by patients.

Wilate demonstrated high effectiveness in treating bleeding episodes and providing prophylaxis, with 100% of on-demand treatments rated as 'excellent' or 'good' by patients and investigators, and a median annualized bleeding rate of only 1.9 during prophylaxis.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Real-World Data on the Effectiveness and Safety of wilate for the Treatment of von Willebrand Disease. Sholzberg, M., Khair, K., Yaish, H., et al.[2021]

A recombinant von Willebrand factor (rVWF) was successfully used in a patient with von Willebrand disease type 2A to control severe gastrointestinal bleeding, demonstrating its efficacy in acute treatment.

After starting rVWF therapy, the patient experienced a significant reduction in bleeding symptoms and did not require any red blood cell transfusions for over 3 months, indicating its potential for both treatment and prophylaxis in managing bleeding episodes.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Recombinant von Willebrand factor for severe gastrointestinal bleeding unresponsive to other treatments in a patient with type 2A von Willebrand disease: a case report. Brown, R.[2018]

Citations

1. New Zealand pubmed.ncbi.nlm.nih.gov

Pharmacokinetic-Pharmacodynamic Comparison of Recombinant and Plasma-Derived von Willebrand Factor in Patients with von Willebrand Disease Type 3. [2023]

2. United States pubmed.ncbi.nlm.nih.gov

Outcomes in Patients With von Willebrand Disease Receiving Recombinant von Willebrand Factor on Demand and in Surgical Settings: Chart Review. [2023]

3. England pubmed.ncbi.nlm.nih.gov

Prophylaxis with recombinant von Willebrand factor in patients with type 3 von Willebrand disease: Results of a post hoc analysis from a phase 3 trial. [2023]

4. United States pubmed.ncbi.nlm.nih.gov

rVWF: treatment finally reaches the modern age. [2021]

5. United States pubmed.ncbi.nlm.nih.gov

Recombinant von Willebrand factor: preclinical development. [2006]

6. England pubmed.ncbi.nlm.nih.gov

Phase 3 study of recombinant von Willebrand factor in patients with severe von Willebrand disease who are undergoing elective surgery. [2023]

7. Germany pubmed.ncbi.nlm.nih.gov

Real-World Data on the Effectiveness and Safety of wilate for the Treatment of von Willebrand Disease. [2021]

8. England pubmed.ncbi.nlm.nih.gov

Recombinant von Willebrand factor for severe gastrointestinal bleeding unresponsive to other treatments in a patient with type 2A von Willebrand disease: a case report. [2018]

9. England pubmed.ncbi.nlm.nih.gov

Design, synthesis and biological activity of selective and orally available TF/FVIIa complex inhibitors containing non-amidine P1 ligands. [2006]

10. England pubmed.ncbi.nlm.nih.gov

Expanding molecular transition metal cubane clusters of the form [M4(μ3)-O)4]12+: syntheses, spectroscopic and structural characterizations of molecules M4(μ3-O)4(O2P(Bn)2)4(O4), M = V(V) and W(V). [2011]

11. Switzerland pubmed.ncbi.nlm.nih.gov

Biospeciation of Potential Vanadium Drugs of Acetylacetonate in the Presence of Proteins. [2020]

12. United States pubmed.ncbi.nlm.nih.gov

Revisiting the Three Vanadium Sandwich-Type Polyoxometalates: Structures, Solution Behavior, and Redox Properties. [2022]

13. United States pubmed.ncbi.nlm.nih.gov

Decavanadate inhibits catalysis by ribonuclease A. [2014]